accountU.S. regulators should require drugmakers to study the potential heart risks of all new diabetes medicines, an advisory panel said on Wednesday.
Join Business Exchange
to access the most
relevant content for you,
filtered by like-minded
business professionals.
Learn more
Reactions to US advisers urge higher bar for new diabetes drugs
Join Business Exchange
to access the most relevant content for you, filtered by like-minded business professionals. Learn more
account
